// App-Quantinova.ai

DMT42 : Fetal Exposure with Ponesimod Treatment across Clinical Development Studies

Researchers

Presenter

  • Mauricio Rosas-Ballina

Principal Investigators

  • Annette Wooller

  • Robyn Jones

  • Andrea Vaclavkova

  • Eva K Havrdova

Medical Centers

  • Actelion Pharmaceuticals, Part of Janssen Pharmaceutical Companies, Allschwil, Switzerland

  • Janssen Medical Affairs, Janssen-Cilag Ltd, High Wycombe, UNITED KINGDOM

  • Johnson & Johnson, New Brunswick, NJ

  • 6First Medical Faculty, Charles University in Prague Prague Czech Republic

Locations

  • Switzerland

  • United States

  • United Kingdom

  • Czech Republic

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Paraoxonase 1

Drug/Treatment

  • Ponesimod

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved